Fig. 2.
Impact of DEL-22379 on cell viability and apoptosis in thyroid tumor cells. 8505c and OCUT2 cells carry BRAFV600E and CAL62 and HTH83 cells carry K-, and H-RAS mutations, respectively. A XTT-reduction cell viability assay showing fold-change of living cells over time: 24, 48 and 72 h (h), in the presence of 10% FBS plus 1 µM DEL-22379 or vehicle (DMSO). Results are expressed as mean (SD) of at least 3 independent experiments. Statistical significance of differences elicited by DEL-22379 was calculated by two-way ANOVA (*)p = 0.05–0.01, (**)p = 0.01–0.001. B BrdU incorporation assay after 72 h of treatment with 1 µM (D1) or 5 µM (D5) DEL-22379, 10 µM U0126 or vehicle (DMSO). Results are expressed as mean (SD) of fold-change and statistical significance of differences compared with a vehicle was calculated by paired t test. (*) p = 0.05–0.01, (**)p = 0.01–0.001, (***) p < 0.001. C YOPRO-1/PI incorporation assay showing percentage of live, apoptotic and necrotic cells after 24 h in the presence of 10% FBS plus vehicle (DMSO), 1 µM DEL-22379 (D1), 10 µM DEL-22379 (D10) or 10 µM U0126. Results are expressed as the percentage of mean (SD) of cell number. Statistical significance of differences elicited by the treatments compared with a vehicle was calculated using a two-tailed t test. (*)p = 0.05–0.01, (**)p = 0.01–0.001